Interleukin Genetics CEO Presents at Opening Session of EuroPerio 5 Meeting.WALTHAM, Mass. -- Interleukin Genetics (AMEX AMEX See: American Stock Exchange : ILI) today announced that its Chief Executive Officer, Ken Kornman, DDS (1) (Digital Data Storage) See DAT. (2) (Data Dictionary System) See QuickBuild and OpenDDS. (3) (Dataphone Digital S , PhD, presented during the Opening Session, "50 Years of Periodontology periodontology, n See periodontics. : From the Past to the Future" at the fifth triennial tri·en·ni·al adj. 1. Occurring every third year. 2. Lasting three years. n. 1. A third anniversary. 2. A ceremony or celebration occurring every three years. meeting of the European Federation of Periodontology in Madrid, Spain. In his keynote address to over 4,000 participants, Dr. Kornman spoke about the technologies that will change the future of the practice of periodontics periodontics: see dentistry. including the research by Interleukin Genetics' involving its pioneering work in IL-1. "We believe that the future of medicine and dentistry is preventive care and wellness instead of treatment of active disease processes. As individuals look forward to longer lifespans, they want to be well and active and will expect predictive and preventive medicine preventive medicine, branch of medicine dealing with the prevention of disease and the maintenance of good health practices. Until recently preventive medicine was largely the domain of the U.S. . For these reasons, there will be more emphasis on risk factors, such as genetics, in the prediction of who is likely to develop more aggressive periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where and who will respond better to certain treatments," commented Ken Kornman "We are leading in this effort at Interleukin through our research into the genetics of inflammation with our work in IL-1, where we have already developed DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. risk assessment tests for cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and for periodontitis periodontitis Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues. ." About Periodontal Disease Periodontal disease is a bacterially induced inflammatory disease that destroys the bone and soft tissues that support the teeth and ultimately leads to tooth loss. Individuals with periodontal disease have been shown to also be at increased risk for certain diseases involving inflammation, including pre-term child birth and cardiovascular disease. About Interleukin Interleukin Genetics is a biotechnology company focused on developing and commercializing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment, and its current development programs focus on osteoporosis, and weight management. Interleukin expects that these programs will also lead to products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com. Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to complete all of our key milestones with regard to Alticor programs, our ability to make progress in advancing our core technologies and our ability to launch new commercial products and those risks and uncertainties described in our annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion